DB:20B

Stock Analysis Report

Executive Summary

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Biomark Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 20B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.6%

20B

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

416.7%

20B

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 20B exceeded the German Biotechs industry which returned 10% over the past year.

Return vs Market: 20B exceeded the German Market which returned 12.8% over the past year.


Shareholder returns

20BIndustryMarket
7 Day-1.6%0.4%-0.9%
30 Day-20.5%-3.2%-0.4%
90 Day-26.2%4.6%2.3%
1 Year416.7%416.7%10.3%10.0%16.3%12.8%
3 Year113.8%113.8%49.4%47.8%15.8%5.7%
5 Year-50.8%-50.8%13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Biomark Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biomark Diagnostics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Biomark Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biomark Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 20B’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Biomark Diagnostics regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Biomark Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomark Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Biomark Diagnostics performed over the past 5 years?

43.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 20B is currently unprofitable.

Growing Profit Margin: 20B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 20B is unprofitable, but has reduced losses over the past 5 years at a rate of 43% per year.

Accelerating Growth: Unable to compare 20B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 20B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 20B's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Biomark Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: 20B has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 20B has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 20B is debt free.

Reducing Debt: 20B's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 20B has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 20B's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 20B has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 20B has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Biomark Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 20B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 20B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 20B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 20B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 20B's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Rashid Bux 0

5.7yrs

Tenure

CA$240,000

Compensation

Mr. Rashid Ahmed Bux, B.Sc., MBA, is the Founder of BioMark Technologies Inc., a bio pharm business, which has achieved Phase III status in an unprecedented 3 years and has been it Chief Executive Officer  ...


CEO Compensation Analysis

Compensation vs Market: Rashid's total compensation ($USD181.63K) is below average for companies of similar size in the German market ($USD413.13K).

Compensation vs Earnings: Rashid's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Rashid Bux
Founder5.7yrsCA$240.00k0.41% CA$37.2k
Gina Huang
CFO & Project Director2.7yrsno datano data
Thomas Malcolm
Chief Scientific Officer0yrsno datano data
Neal Kaplan
Chief Financial Officer of US0yrsno datano data
Daniel Sitar
Principal Scientific Advisor0yrsno datano data
James Bond
Chief of Surrey Hospital Thoracic Surgery Team1.1yrsno datano data

2.7yrs

Average Tenure

Experienced Management: 20B's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rashid Bux
Founder5.7yrsCA$240.00k0.41% CA$37.2k
Bill Good
Member of Media Advisory Board0yrsno datano data
Bramhanand Ramjiawan
Independent Director5.4yrsno datano data
Brian Cheng
Independent Director5.4yrsno datano data

5.4yrs

Average Tenure

Experienced Board: 20B's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 20B insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.


Top Shareholders

Company Information

Biomark Diagnostics Inc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biomark Diagnostics Inc
  • Ticker: 20B
  • Exchange: DB
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €8.967m
  • Shares outstanding: 72.31m
  • Website: https://www.biomarkdiagnostics.com

Location

  • Biomark Diagnostics Inc
  • 165–10551 Shellbridge Way
  • Richmond
  • British Columbia
  • V6X 2W8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BUXCNSX (Canadian National Stock Exchange)YesCommon SharesCACADNov 2014
20BDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2014
BMKD.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2014

Biography

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a research collaboration with the University of Maryland School of Medicine related to the discovery and validation of biomarkers using a combinatorial technology approach. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 23:57
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.